Suggested Readings

Sphingosine-1 phosphate receptor modulators: the next wave of oral therapies in inflammatory bowel disease.

Choden T, et al. Gastroenterol Hepatol (NY). 2022;18(5):265-271.

Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis—a unique therapeutic target in inflammatory bowel disease.

Wang J, et al. Aliment Pharmacol Ther. 2022;55(3):277-291.

Ozanimod as induction and maintenance therapy for ulcerative colitis.

Sandborn WJ, et al. N Engl J Med. 2021;385(14):1280-1291.

P405 Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension.

Panaccione R, et al. J Crohns Colitis. 2023;17(suppl 1):i534-i535. DOI: 10.1093/ecco-jcc/jjac190.0535.

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.

Sandborn WJ, et al. Lancet. 2023;401(10383):1159-1171. 

Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk.

Sugahara K, et al. Br J Pharmacol. 2017;174(1):15-27. 

Approach to the management of recently diagnosed inflammatory bowel disease patients: a user's guide for adult and pediatric gastroenterologists.

Agrawal M, et al. Gastroenterology. 2021;161(1):47-65.

STRIDE-II: An update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD.

Turner D, et al. Gastroenterology. 2021;160(5):1570-1583.

A treat-to-target update in ulcerative colitis: a systematic review.

Ungaro R, et al. Am J Gastroenterol. 2019;114(6):874-883.

From bench to bedside: fecal calprotectin in inflammatory bowel diseases clinical setting.

Mumolo MG, et al. World J Gastroenterol. 2018;24(33):3681-3694.

DOP37 Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study.

Danese S, et al. J Crohns Colitis. 2023;17(suppl 1):i101-i102. DOI: 10.1093/ecco-jcc/jjac190.0077.

Defining success in treating patients with inflammatory bowel disease.

Theede K, Burisch J. Expert Rev Clin Immunol. 2017;13(7):645-647.

Related activities
1.00 CME/CE

Buffing Up on New Oral UC Therapies: What You Need to Know

A CME Circuit Training™ Activity

Faculty: Florian Rieder, MD
Release: 05/17/2023
Expiration: 05/17/2024